According to Model 4, the sensitivity, specificity, and accuracy of the «ΔStO2» indicator for predicting pCR in patients with triple-negative and HER2-positive breast cancer were 60.9%, 80.9%, and 74.3%, respectively (65 patients). This evidence concerns the gene ERBB2 and breast carcinoma.